Information sent to healthcare professionals in February 2009 about the safety of medicines

A list of letters sent to healthcare professionals in February 2009, to inform of new safety information and advice.

Date issued Product Safety information
Week commencing Feb 2 Fareston (toremifene)PDF file (opens in new window) (39Kb) Risk of QT prolongation
See also Drug Safety Update February 2009, p 7
Feb 9 Avastin (bevacizumab)PDF file (opens in new window) (35Kb) Reports of severe eye inflammation and sterile endophthalmitis after off-label intravitreal use in Canada
Feb 20 Raptiva (efalizumab)PDF file (opens in new window) (560Kb) Recommendation to suspend marketing authorisation as risks outweigh benefits

See also a message sent through the Department of Health’s Central Alerting System about advice for children’s over-the-counter cough and cold medicines (external link).

Page last modified: 04 March 2009